Accessibility Menu
Biotron logo

Biotron(ASX) BIT

Market CapA$5.57MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2001)-99%
5 Year-96%
1 Year-50%
1 Month+0%
A$0.00
+0.00%
+0.00Today
Biotron last closing stock price
MetricPriceDate
Last closeAUD 0.002026-08-14
Biotron stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0%AUD 0.002026-08-07
1 month+0%AUD 0.002026-07-15
3 month-33.33%AUD 0.002026-05-15
Year to date-33.33%AUD 0.002025-12-31
1 year-50%AUD 0.002025-08-14
3 year-92.38%AUD 0.032023-08-15
5 year-95.79%AUD 0.052021-08-13
Since inception-99.32%AUD 0.292001-01-25

Biotron Financials at a Glance

Market Cap

A$5.57MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

A$1.81M

Net Income (TTM)

-A$3.35M

EPS (TTM)

-A$0.00

P/E Ratio

-1.18

Dividend

A$0.00

Beta (Volatility)

-0.14 (Low)

Price

A$0.00

Volume

1,857,517

Open

A$0.00

Previous Close

A$0.00

Daily Range

A$0.00 - A$0.00

52-Week Range

A$0.00 - A$0.01

Estimated Earnings Date

Feb 26, 2026

BIT News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Biotron

Biotron Limited is an Australian biotechnology firm focused on developing small molecule therapies to combat various viral illnesses. The company's flagship antiviral compound, BIT225, is currently in Phase II clinical trials targeting infections caused by SARS-CoV-2, HIV-1, and hepatitis C virus.

Products and Services
  • BIT225: An antiviral compound in Phase II trials
  • Research and development of therapies for viral infections
  • Collaboration with research institutions for innovative solutions
Growth Outlook
  • BIT225 shows promise in treating multiple viral infections
  • Ongoing clinical trials may lead to significant market opportunities
  • Strategic partnerships could enhance research capabilities and funding
Financial Highlights
  • Recent quarterly revenue of AUD 1,644,114 indicates potential growth
  • Cash and cash equivalents increased to AUD 1,642,799 in Q2 2025
  • Operating income improved significantly, reflecting operational efficiency
Biotron Limited operates in a dynamic sector with a focus on innovative antiviral therapies. The company's lead product, BIT225, is positioned to address critical health challenges posed by viral infections. The ongoing clinical trials and potential market applications of BIT225 could provide substantial growth opportunities. Recent financial data indicates a positive trend, with increasing revenue and cash reserves, suggesting a strengthening operational foundation. The biotechnology industry is known for its volatility, but Biotron's strategic focus on viral therapies may attract investor interest as the company navigates its clinical development pathway.
AI Generated • Jul 24, 2026

Industry

Biotechnology

CEO

Michelle Miller, PhD

Headquarters

Sydney, NSW 2000, AU

BIT Financials

Key Financial Metrics (TTM)

Gross Margin

190.21%

Operating Margin

222203.69%

Net Income Margin

223061.06%

Return on Equity

-119.12%

Return on Capital

-61.38%

Return on Assets

-50.16%

Earnings Yield

-84.75%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

A$5.57MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

2.79B

Volume

1.86M

Avg. Volume

2.33M

Financials (TTM)

Gross Profit

A$1.79M

Operating Income

-A$3.37M

EBITDA

-A$3.31M

Operating Cash Flow

-A$1.74M

Capital Expenditure

-A$3.07K

Free Cash Flow

-A$1.74M

Cash & ST Invst.

A$1.64M

Total Debt

A$0.00

Biotron Performance Analysis

Biotron annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-06-30AUD 0N/A
20232023-06-30AUD 0N/A
20242024-06-30AUD 0N/A
20252025-06-30AUD 0N/A
Biotron sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-06-30-100.0%
Q22024-12-31N/A
Q42025-06-30-100.0%
Q22025-12-31100.0%
Biotron annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-06-30AUD -0.00N/A
20232023-06-30AUD -0.008.8%
20242024-06-30AUD -0.00-10.8%
20252025-06-30AUD -0.00-90.9%
Biotron sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-06-30-53.3%
Q22024-12-31130.4%
Q42025-06-30-228.6%
Q22025-12-31100.0%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

A$0.00

-100.0%

Gross Profit

-A$783.00

+96.4%

Gross Margin

0.00%

N/A

Market Cap

A$5.57MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

A$1.39M

N/A

Employees

4

N/A

Net Income

-A$920.97K

+30.4%

EBITDA

-A$892.16K

+69.7%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

A$1.64M

+127.6%

Total Debt

A$0.00

-100.0%

Accounts Receivable

A$0.00

N/A

Inventory

A$0.00

N/A

Long Term Debt

A$0.00

N/A

Short Term Debt

A$0.00

-100.0%

Return on Assets

-50.16%

N/A

Return on Invested Capital

-71.46%

N/A

Free Cash Flow

-A$868.42K

+73.4%

Operating Cash Flow

-A$868.42K

+73.4%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
ACR.AXAcrux Limited
A$0.01+0.00%
IBX.AXImagion Biosystems Limited
A$0.01-15.38%
BGT.AXBio-Gene Technology Limited
A$0.02+0.00%
ZLD.AXZelira Therapeutics Limited
A$0.50+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
ONDSOndas
$8.91-0.09%
SMCISuper Micro Computer
$39.16+0.04%
SPCXSpace Exploration Technologies
$141.29-0.03%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$8.64+0.07%

Questions About BIT

What is the current price of Biotron?

Biotron is trading at A$0.00 per share.

What is the 52-week range for Biotron?

Over the past 52 weeks, Biotron has traded between A$0.00 and A$0.01.

How much debt does Biotron have?

As of the most recent reporting period, Biotron reported total debt of A$0.00.

How much cash does Biotron have on hand?

Biotron reported A$931.68K in cash and cash equivalents in its most recent financial results.

What is Biotron’s dividend yield?

Biotron does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.